TY - JOUR
T1 - Clinical assessment of the cancer diagnostic value of prostatic zinc
T2 - A comprehensive needle-biopsy study
AU - Cortesi, M.
AU - Fridman, E.
AU - Volkov, A.
AU - Shilstein, S. Sh
AU - Chechik, R.
AU - Breskin, A.
AU - Vartsky, D.
AU - Kleinman, N.
AU - Kogan, G.
AU - Moriel, E.
AU - Gladysh, V.
AU - Huszar, M.
AU - Ramon, J.
AU - Raviv, G.
PY - 2008/6/15
Y1 - 2008/6/15
N2 - BACKGROUND. The correlation between Zinc concentration in the prostate's peripheral zone to the onset or presence of malignant process needs to be evaluated in detail. METHODS. Zinc concentration was measured in ∼1-4 mm3 segments of fresh needle-biopsy cores, with X-ray fluorescence, and correlated with the histological findings of these tissue segments. RESULTS. Local Zinc concentration is correlated with the presence of cancer (PCa); the higher the Gleason score the greater the Local Zinc depletion. The Zinc value averaged over the entire extracted tissue is specific only to Gleason score 8-9 PCa. The results refer to patients avoiding Zinc-rich supplements since those show elevated prostatic Zinc concentration in identified cancer tissue. A computer simulation analysis of randomly located 0.03-3.3 cm3 lesions, with particular Gleason score and the measured Local Zinc concentration, revealed a potential diagnostic approach definitely superior to PSA, with sensitivity to the tumor grade and with excellent detection capability for Gleason score >6. Further clinical studies have been designed, both on full prostates after radical prostatectomy as well as on biopsy cores at higher resolution, to establish the accuracy of the method for Gleason score = 6. CONCLUSIONS. The PCa diagnostic potential of Local Zinc concentration is confirmed and there is indication that the amount of Zinc depletion could be used as a measure of the Gleason score of the tumor. Local Zinc concentration mapping has the potential to improve patient selection for biopsy, biopsy site selection and local therapy (e.g., Cryotherapy, Brachytherapy) site selection.
AB - BACKGROUND. The correlation between Zinc concentration in the prostate's peripheral zone to the onset or presence of malignant process needs to be evaluated in detail. METHODS. Zinc concentration was measured in ∼1-4 mm3 segments of fresh needle-biopsy cores, with X-ray fluorescence, and correlated with the histological findings of these tissue segments. RESULTS. Local Zinc concentration is correlated with the presence of cancer (PCa); the higher the Gleason score the greater the Local Zinc depletion. The Zinc value averaged over the entire extracted tissue is specific only to Gleason score 8-9 PCa. The results refer to patients avoiding Zinc-rich supplements since those show elevated prostatic Zinc concentration in identified cancer tissue. A computer simulation analysis of randomly located 0.03-3.3 cm3 lesions, with particular Gleason score and the measured Local Zinc concentration, revealed a potential diagnostic approach definitely superior to PSA, with sensitivity to the tumor grade and with excellent detection capability for Gleason score >6. Further clinical studies have been designed, both on full prostates after radical prostatectomy as well as on biopsy cores at higher resolution, to establish the accuracy of the method for Gleason score = 6. CONCLUSIONS. The PCa diagnostic potential of Local Zinc concentration is confirmed and there is indication that the amount of Zinc depletion could be used as a measure of the Gleason score of the tumor. Local Zinc concentration mapping has the potential to improve patient selection for biopsy, biopsy site selection and local therapy (e.g., Cryotherapy, Brachytherapy) site selection.
KW - Local therapy control
KW - Needle biopsy
KW - PCa detection ROC curves
KW - PSA
KW - Patient selection for biopsy
KW - Prostate cancer
KW - Prostatic Zinc concentration
UR - http://www.scopus.com/inward/record.url?scp=44849140582&partnerID=8YFLogxK
U2 - 10.1002/pros.20766
DO - 10.1002/pros.20766
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18386292
AN - SCOPUS:44849140582
SN - 0270-4137
VL - 68
SP - 994
EP - 1006
JO - Prostate
JF - Prostate
IS - 9
ER -